In connection with the release of the financial interim report for the third quarter of 2023, Kancera AB (publ) provides an operational update regarding its fractalkine blockers KAN567 and KAND145, both in clinical stage. Further, the company reports that...
Read MoreThe period in brief – financial summary for the third quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 9,2 million (SEK 8,7 million). Operating income for the third quarter amounted to SEK...
Read MoreKancera AB (publ) today reports that the Finnish regulatory agency (FIMEA) has approved Kancera’s application to conduct a phase I study of KAND145, the company’s second generation fractalkine blocking candidate drug.
Read MoreKancera AB (publ) today announces that the top line results from the FRACTAL study are delayed. The company expects that results will be presented by the end of December 2023.
Read MoreKancera AB (publ) announces that Dr. Markus Jerling has been appointed as new Chief Medical Officer, effective from September 1, 2023.
Read More